CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 42 enrolled
Drug / intervention
Fluoxetine+Olanzapine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00188942
NCT00188942Phase 4Completed
CompareCT.gov

Neural Correlates of Emotional Processing in Depressed and Remitted Bipolar and Unipolar Depressed Subjects: An fMRI Investigation

University Health Network, Toronto·interventional·Posted Sep 16, 2005·Updated Feb 8, 2013

In Brief

A Phase 4 clinical trial evaluating Fluoxetine+Olanzapine, Olanzapine, and 1 other intervention for Major Depressive Disorder. Completed, enrolled 42 participants across 2 sites.

Detailed Summary

This study employs functional magnetic resonance imaging to compare brain activation patterns during a depressive episode in patients diagnosed with bipolar disorder, major depressive disorder, and a group of healthy control subjects. Depressed patients will be treated with a combination of fluoxetine and olanzapine and undergo MRI scans before, during, and after pharmacotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesCanada
CollaboratorsEli Lilly and Company

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartFeb 1, 2005
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 20.8 years ago

Interventions

Fluoxetine+Olanzapinedrug

Olanzapinedrug

Functional Magnetic Resonance Imagingprocedure